Saliva-based molecular testing for SARS-CoV-2

Diana Rose E Ranoa; Robin L Holland; Fadi G Alnaji; Kelsie J Green; Leyi Wang; Christopher Byron Brooke; Martin D. Burke; Timothy M. Fan; Paul J Hergenrother

Saliva-based molecular testing for SARS-CoV-2

Diana Rose E Ranoa (Inventor), Robin L Holland (Inventor), Fadi G Alnaji (Inventor), Kelsie J Green (Inventor), Leyi Wang (Inventor), Christopher Byron Brooke (Inventor), Martin D. Burke (Inventor), Timothy M. Fan (Inventor), Paul J Hergenrother (Inventor)

Research output: Patent

Abstract

A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.

Original language	English (US)
U.S. patent number	11926877
Filing date	6/17/21
State	Published - Mar 12 2024

Library availability

Discover UIUC Full Text

Cite this

@misc{8c13d0035a394f959ff69287ce4949af,

title = "Saliva-based molecular testing for SARS-CoV-2",

abstract = "A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.",

author = "Ranoa, {Diana Rose E} and Holland, {Robin L} and Alnaji, {Fadi G} and Green, {Kelsie J} and Leyi Wang and Brooke, {Christopher Byron} and Burke, {Martin D.} and Fan, {Timothy M.} and Hergenrother, {Paul J}",

year = "2024",

month = mar,

day = "12",

language = "English (US)",

type = "Patent",

note = "11926877",

}

TY - PAT

T1 - Saliva-based molecular testing for SARS-CoV-2

AU - Ranoa, Diana Rose E

AU - Holland, Robin L

AU - Alnaji, Fadi G

AU - Green, Kelsie J

AU - Wang, Leyi

AU - Brooke, Christopher Byron

AU - Burke, Martin D.

AU - Fan, Timothy M.

AU - Hergenrother, Paul J

PY - 2024/3/12

Y1 - 2024/3/12

N2 - A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.

AB - A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.

M3 - Patent

M1 - 11926877

Y2 - 2021/06/17

ER -

Saliva-based molecular testing for SARS-CoV-2

Abstract

Library availability

Fingerprint

Cite this